Business & Industry
Business & Industry
Er-Kim Announces Exclusive Agreement with CNX Therapeutics to Distribute Oncology Products Across CEE and Turkey
Partnership will broaden portfolio distribution of oncology products to cancer patients in the specified regions
Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced a distribution agreement withย CNX Therapeuticsย to supply selected oncology products across Central...
Business & Industry
Chinese Pharmaceutical Firms Turn to Local Reagent Suppliers
The Chinese pharmaceutical firms are increasingly looking out for the local reagent suppliers so as to cut the costs as well as delivery times. Growing import tariffs because of the US-China trade war, as well as concerns with regard...
BioPharma
Medicine Manufacturers from Europe Eyeing US Tariff Move
The medicine manufacturers from Europe are bracing for President Donald Trumpโs plan to slap tariffs of almost 250% on medicine imported from the EU.
The declaration made by Trump that the drug exports of Europe will be hit with certain...
BioPharma
America’s AI Action Plan Boosts Pharmaceutical Innovation
Accelerating Pharmaceutical and Biopharmaceutical Innovation through Americaโs AI Action Plan
Americaโs AI Action Plan, unveiled in July 2025, lays out a comprehensive strategy to propel the United States to the forefront of global AI leadership. Within its three pillarsโinnovation, infrastructure,...
BioPharma
Trump To Roll-Out 340B Drugs Discount Program in 2026
The Trump administration is going to pilot a voluntary program in 2026, wherein the pharmaceutical companies can offer rebates for certain drugs to hospitals that are participating in the 340B drugs discount program.
The pilot happens to depart from the...
BioPharma
60-Day Window by Trump for Firms to Lower Their Drug Prices
President Donald Trump of the USA has sent letters to the drug company CEOs demanding they lower their drug prices. The letters that have been posted by Trump on social media Say name-brand drug prices are almost three times...
BioPharma
Bavarian Nordic Agrees for a $3 Bn Take-Private Offer
Bavarian Nordic, the vaccine maker, on July 28 said that it has agreed in principle for roughly $3 bn take-private offer from private equity firms Permira and Nordic Capital.
Apparently, the board of directors of the company plan to unanimously...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















